Home World News Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours World News Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 310 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining May 25, 2021 Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... January 31, 2022 Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with... July 21, 2026 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Camizestrant EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... Self Destruction ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...
